Slides
Page 1
CORONA Remedies LimitedInvestor Presentation: October 2026
Page 2
This presentation and the accompanying slides (the “Presentation”), which have been prepared byCORONA Remedies Limited(the “Company”), havebeen prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities,and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of theCompany will be made except by means of a statutory offering document containing detailed information about the Company.This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes norepresentation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness andreasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you mayconsider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that areindividually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject toknown and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, theperformance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide,competition, the company’s ability to successfully implement its strategy, the Company’s future levels of growth and expansion, technologicalimplementation, changes and advancements, changes in revenue, income or cash flows, the Company’s market preferences and its exposure to marketrisks, as well as other risks. The Company’s actual results, levels of activity, performance or achievements could differ materially and adversely fromresults expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in thisPresentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company andthe Company is not responsible for such third-party statements and projections.All Maps used in the presentation are not to scale. All data, information, and maps are provided "as is" without warranty or any representation ofaccuracy, timeliness or completeness Safe Harbor 2
Page 3
3 Operational & Financial PerformanceFinancial & Operational Performance for Q2 and H1 FY27About usOverview of CORONARoad AheadKey Growth StrategiesCORONA: Outpacing IPM GrowthCORONA vs. IPMAnnexuresManagement Team and Historical Financial Performance ContentsFocused Brand Building ApproachStrong brand recall across Therapeutic Areas
Page 4
4 REVENUEKey HighlightsFinancial HighlightsEBITDAPAT Q2FY27 (Y-o-Y) H1 FY27 (Y-o-Y)Key Highlights for Q2 & H1 FY27H1 FY27INR 96.0 Cr21.7% EBITDA Margin+ 22.3%INR 189.1 Cr21.9% EBITDA Margin+27.5%32.9%ROE#INR 60.3 Cr13.7% PAT Margin+15.3%INR 120.4 Cr13.9% PAT Margin+22.2%₹19.7/-EPS*INR 441.2 Cr+ 22.2%INR 863.6 Cr+22.0%49.8%ROCE#Return RatiosIndia business contributed97.1% oftotal revenue in H1 FY27.Chronic and sub-chronictherapiescontribute~72.1%in H1 FY27.Improved our Rank to 26thin MATSep-26 from 27thin MAT Mar-26 inIPM[1]Renewed EU-GMPcertification forthe Oral Solid Dosage line at Bhaylaplant in May 2026.InauguratedHormone FacilityatBhayla withEU-GMP certificationinJune 2026.Received ANVISA GMP (Brazil)Certificationfor Bhayla OSD &Hormone Manufacturing Facility inOctober 2026.#Annualised*Not Annualised[1] Pharmatrac
Page 5
5 Q2 & H1FY27 Consolidated Profit & Loss StatementY-o-YH1FY26H1FY27Y-o-YQ2FY26Q2FY27Profit and Loss (INR Crores)22.0%707.7 863.6 22.2%361.1 441.2 Revenue from Operations81.0%81.7%81.0%81.8%Gross Margin (%)200.4 246.3 103.0 124.2 Employee Cost224.6 270.2 111.0 140.5 Other Expenses27.5%148.2 189.1 22.3%78.5 96.0 EBITDA20.9%21.9%21.7%21.7%EBITDA Margin (%)18.1 28.3 9.2 15.1 Depreciation & Amortization4.3 5.6 2.3 2.5 Other Income3.9 5.4 1.9 2.8 Finance Cost-0.0 0.1 0.2 0.1 Share in Profit/(loss) in Associate130.5 161.1 69.8 80.8 Profit before Tax32.0 40.7 17.5 20.4 Tax Expense22.2%98.5 120.4 15.3%52.3 60.3 Profit After Tax (PAT) *13.9%13.9%14.5%13.7%PAT Margin (%) ** PAT & PAT Margin was lower in Q2 due to higher depreciation & amortization for our newly commissioned facilities and acquisition of brands.
Page 6
6 Consolidated Balance Sheet * Short Term Borrowings includes Overdraft against Fixed Deposit shown under Other Financial Assets & Bank Balances (FD – 146.8 Cr & OD – 94.3 Cr) Mar-26Sep-26Equity & Liabilities (INR Crores)Mar-26Sep-26Assets (INR Crores)746.9 805.1 Total Equity856.8 773.1 Non - Current Assets61.2 61.2 Share Capital291.1 425.2 Property, plant and equipment685.7 744.0 Other Equity143.1 21.8 Capital work-in-progress97.1 108.6 Non-Current Liabilities262.8 246.9 Intangible assets26.1 26.3 Investments accounted as per equity methodFinancial LiabilitiesFinancial Assets0.0 0.3 Borrowings0.2 0.2 Investments66.1 75.4 Provisions129.9 50.9 Other Financial Assets12.2 15.7 Deferred tax liabilities (net)0.0 0.0 Loans18.9 17.3 Lease Liabilities3.6 1.8 Other non-current assets361.2 333.0 Current Liabilities348.3 473.7 Current AssetsFinancial Liabilities125.0 170.7 Inventories142.9 94.3 (i) Borrowings *Financial Assets90.3 115.7 (ii) Trade Payables145.6 170.6 (i)Trade receivables76.5 64.0 (iii) Other Financial Liabilities1.8 1.6 (ii)Cash and cash equivalents7.0 8.4 Other Current Liabilities42.3 97.2 (iii)Bank balances3.1 3.3 Lease Liabilities0.3 0.1 Loans8.4 11.7 Current Tax Liabilities0.3 0.1 Other Financial Assets33.0 35.7 Provisions33.1 33.4 Other Current Assets1,205.1 1,246.7 Total Equity & Liabilities1,205.1 1,246.7 Total Assets
Page 7
7 Consolidated Abridged Cash Flow StatementH1FY26H1FY27Particulars (INR Crores)130.5161.1Profit Before Tax23.333.7Adjustments for: Non - Cash Items / Other Investment or Financial Items153.8194.8Operating profit before working capital changes-17.7-48.6Changes in working capital136.0146.3Cash generated from Operations-22.6-33.5Income taxes paid (net)113.4112.7Net Cash from Operating Activities-41.33.3Net Cash from Investing Activities-73.6-116.3Net Cash from Financing Activities-1.4-0.2Net Increase/(Decrease) in Cash and Cash equivalents3.21.8Add: Cash & Cash equivalents at the beginning of the period1.81.6Cash & Cash equivalents at the end of the period(40.4)(53.9)Net Debt / (Cash)
Page 8
8 About usOverview of CORONACORONA: Outpacing IPM GrowthCORONA vs. IPMOperational & Financial PerformanceFinancial & Operational Performance for Q2 and H1 FY27Road AheadKey Growth StrategiesAnnexuresManagement Team and Historical Financial Performance ContentsFocused Brand Building ApproachStrong brand recall across Therapeutic Areas
Page 9
CORONA’s3CPhilosophy•Ruthless Execution•Internal Promotion•Adaptability•HumblenessCulture•Accepting Mistakes and improving•Robust Inorganic OpportunitiesCourage•Global Quality Products•Value Creation for Stakeholders•Long Term Sustainable GrowthCommitment9 CORONA’s 3C Philosophy
Page 10
2005-12Launch of multispecialty division Xemxin 2005 and Aarush in 2008Commenced production at 1stmanufacturing plant at Solan, Himachal PradeshEntry into women’s healthcare business2018-21Acquisition of 6 brands for sale in India from Abbott India LimitedInvestment in La Chandra Pharma lab Private Limitedfor backward integration into APIsCommencement of production at manufacturing plant at Ahmedabad, Gujarat2023-24Launch of divisionBlaze (urology)Purchased the brand Myoril(in India) fromSanofi Healthcare India Private LimitedReceivedEU GMP accreditation for the manufacturing plant at Ahmedabad, Gujarat2004Founded in 2004 and launch of first division, later named as ‘Pioneer’ division in 20102013-172022In -licensing arrangement with Ferring Pharmaceuticals Private Limited to market certain products under women’s health and urologyLaunch of division Radiance(cardio-diabetic) & Solaris (gynecology)2025-26Acquisition of 7 brands from Bayer Zydus Pharma LtdListing on NSE & BSE in December 2025ReceivedEAEU GMP accreditation for the manufacturing plant at Ahmedabad, GujaratAcquisition of Wokadinefrom Dr. Reddy’s Laboratories LtdLaunch of 1stcardiological division: WellnessPurchased the brands StelbidandVitneurinfrom Glaxo Group Limited 10 Journey over the years2026-27Renewed EU-GMP certification for the Oral Solid Dosage line at Bhayla plant in May 2026Inaugurated Hormone Facility at Bhayla with EU-GMP certification in June 2026Received Brazilian GMP (ANVISA)certification at Bhayla plant OSD & Hormone in Oct-26
Page 11
11Source: PharmatracNotes: [1] By Domestic Sales between MAT Sep-25 and MAT Sep-26 | [2] Ranking under each therapy as per MAT Sep-26 in addressable market CORONA Remedies at a Glance EU-GMP, EAEU-GMP, ANVISA-GMP& WHO-GMP approved Gujarat facilitiesWHO-GMP approved Himachal Pradesh facility #5in Women’s Healthcare#5 in Pain Management #12in Urology#19 in Cardio-Diabeto 72.1%Chronic portfolio contributionfor H1FY27 81Brands with 33Engines Brands 97.1%Revenue from India Businessfor H1FY27 Jumped 6 ranks in 3 yearsOver MAT Sep-23 to MAT Sep-26
Page 12
12 CORONA’s Competitive Edge Lies in Execution Excellence *PharmaTrac MAT Sep-26# Internal Data Market Share Gains & New LaunchesConsistently delivering volume growth with market share gain, new product launches, geographical expansion and field force expansion Ability to Create & Scale BrandsEstablished track record of building doctor-trusted brands across chronic and sub-chronic segments. 4 brandscrossed INR 100 Cr annual sales in MAT Sep-26 (with 1 brand crossing INR 200 Cr)Well-Diversified Brand Portfolio#Top 5 brands account for ~36% and Top 10 brands account for ~53% of revenue, ensuring diversified and sustainable growthMiddle of the Pyramid ApproachFocus on specialist doctorswith marketing and distribution in urban and semi-urban markets with higher prescription growthStrategic shift to Chronic & sub-Chronic segment#Shifted Portfolio Mix from 70:30 to 28:72(Acute:Chronic) from FY13 to FY26, driving Higher Customer Stickiness and Margin Expansion India Focused Pharmaceutical CompanyRevenue from India Business contributes 97.1 % in H1FY27 and Climbed 6 Ranks in 3 Years*
Page 13
Himachal PradeshInstalled capacity of ~403 Mntablets/capsules & 10 Mnliquid bottlesWHO-GMP & Uganda NDAcertificationsGujaratInstalled capacity of ~1.25 Bn*tablets/capsules & 20 MnsachetsCertified by EU-GMP, EAEU, WHO GMP, Uzbekistan GMP, ANVISA & DSIR IndiaHormone manufacturing facilitybegan operationsQuality Focused State of the Art Manufacturing Facilities 13*Includes additional commercial production of 400 Mn tablets commenced on 22ndDecember 2025 at the Gujarat FacilityTwo DSIR approved R&D Facilities located within the manufacturing facilities for lean and efficient operationsPan-India Presencewith Robust Distribution Network & Medical Representatives (MR) TeamGujaratEU-GMP, ANVISA approved Hormone FacilityInstalled capacity of 194 Mn Tablets/Capsules & 1.5 Mn Ointments/GelsTotal Installed Capacity Formulations*1.84 Bn units p.a. Sachets 20 Mn units p.a. Bottles10 Mn units p.a. Ointments/Gels1.5 Mn units p.a.
Page 14
14 About usOverview of CORONACORONA: Outpacing IPM GrowthCORONA vs. IPMOperational & Financial PerformanceFinancial & Operational Performance for Q2 and H1 FY27Road AheadKey Growth StrategiesAnnexuresManagement Team and Historical Financial Performance ContentsFocused Brand Building ApproachStrong brand recall across Therapeutic Areas
Page 15
15 1.5 1.51.81.92.12.33.1FY20 FY21 FY22 FY23 FY24 FY25 FY30P55%45%FY2557% - 59%41% - 43%FY30PChronic AcuteCAGR 7.5% – 8.5%CAGR 8.5% – 9.5%With growth in chronic segment expected to outpace acute segmentIPM is poised to grow at CAGR of 8-9% till FY30Improving life expectancy and changing demographic profile01Improvement in health insurance penetration03Rising income levels and greater awareness on health04 Rising prevalence of chronic diseases02 Growth drivers for domestic formulations industryINR Trillion Source: CRISIL Intelligence Indian Pharmaceutical Market: High-Growth Landscape
Page 16
Source: PharmaTrac – Q2 FY27, MAT Sep-23 to MAT Sep-26IPM – Indian Pharmaceutical Market Chronic IPM Vs CORONAOverall IPM Vs CORONA12.0%22.5%1.9xSectorSegmentCORONA Remedies: Consistently outperforming IPM14.9%29.0%1.9x8.1%16.9%2.1x10.6%19.6%1.8xQ2FY27(Quarter)MAT Sep-23toMAT Sep-26(3 years)IPM CORONAIPM CORONA
Page 17
17 Consistently outperformingIPM in all metrics across timeframes Source: PharmaTrac – Q2 FY27, MAT Sep-23 to MAT Sep-26IPM – Indian Pharmaceutical Market CORONA Remedies: Consistently outperforming IPM2.3%6.5%2.9x6.1%8.9%1.5x3.6%7.0%1.9x12.0%22.5%1.9xQ2FY27(Quarter)2.5%8.2%3.3x3.8%4.8%1.2x1.8%4.0%2.2x8.1%16.9%2.1xMAT Sep-23toMAT Sep-26(3 years)IPM CORONAIPM CORONAVolumePriceNew IntroductionTotal Revenue
Page 18
187.1%IPM14.5%CORONA2.0x12.0%IPM22.0%CORONA1.8x8.2%IPM27.7%CORONA3.4x13.7%IPM42.8%CORONA3.1xWomen’s HealthcareCardio-DiabetoPain ManagementUrologyCORONA Remediesvs.IPMMAT Sep-23 to MAT Sep-26CORONA Remediesvs.IPMMAT Sep-23 to MAT Sep-26MAT Sep-26(INR Crs) [1]No. of mother brandsRank in IPM [1]Rank in IPM [1]514.1325th456.21919th221.355th56.1812thCardio-DiabetoWomen’s HealthcarePain ManagementUrologySource: Pharmatrac[1] As of MAT Sep-26 in addressable market. Consistently cementing position in segment with focus on four Key Therapies
Page 19
19Source : PharmatracSep-26^Other specialist includes categories (therapies) where CORONA has limited presence Super SpecialistSpecialistOther Specialist^GP39%18%35%8%26%7%55%12%Specialty-wise prescription splitIPM 35%Strategic focus on specialist and super-specialist doctors in the ‘middle of the pyramid’; resulting in a higher prescription contribution compared with IPMFocussed presence in the “Middle of the Pyramid’’ segment
Page 20
20 About usOverview of CORONACORONA: Outpacing IPM GrowthCORONA vs. IPMOperational & Financial PerformanceFinancial & Operational Performance for Q2 and H1 FY27Road AheadKey Growth StrategiesAnnexuresManagement Team and Historical Financial Performance ContentsFocused Brand Building ApproachStrong brand recall across Therapeutic Areas
Page 21
21182010773MAT Sep-23 MAT Sep-2611100 Crs - 200 Crs50 Crs - 100 Crs30 Crs - 50 Crs10 Crs - 30 Crs> 200 Crs Established track record of building and scaling brandsNo. of Brands2938Brands with Sales >INR 10 Crs~79%Contribution to Domestic Sales MAT Sep-26~22%CAGR over MAT Sep-23 to MAT Sep-26“Engine” Brands approach with Successful Scaling Up of Brands33Engine BrandsTop 5 Brands TherapyBrandVMNB-29Pain / AnalgesicsMyorilGynaecologyTriciumCardiacCortelAnti-DiabeticObimetSource: Pharmatrac 1st200 crbrand
Page 22
22 Strategic collaborations for India BusinessAcquisition & Strategic Collaborations for India BusinessSignificantly scaled-up acquired brandsBrandsAcquired FromSr. NoDiloGSK Pharmaceuticals Limited1 StelbidGlaxo Group LimitedVitneurinThyrocabABBOTT India Limited2 ObimetMyorilSanofi Healthcare India Private Limited3 7 Distinct BrandsBayer Zydus Pharma Private Limited4 Wokadine®Dr. Reddy’s Laboratories Limited5 In-Licensing Arrangementfor certain products in Women’s Healthcare and Urology therapiesInvestment in La Chandra Pharmalabs for backward integrationof Hormone API manufacturingFerring Pharmaceuticals, SwitzerlandLa Chandra Pharmalabs Private Limited
Page 23
Strategic Portfolio Diversification & Brand Development 23 Geography WiseTherapy WiseChronic v/s AcuteExpanding and diversifying geographical presence to strengthen and deepen pan-India penetrationFY26Strengthening focus on core therapies and exploring opportunities to broaden the therapy portfolioFY26Accelerating growth in chronic therapies -Outperforming the IPM45.3%54.7%FY16FY16 Source: Internal Data 71.9%28.1%ChronicAcute23.7%6.3%6.2%2.0%63.7%27.5%25.4%11.4%2.9%32.8%Womens HealthcarePain ManagementCardio DiabetoUrologyOthers8.4%66.2%13.8%11.6%WestNorthSouthEast20.0%14.0%45.2%20.8%FY26FY16
Page 24
24 About usOverview of CORONACORONA: Outpacing IPM GrowthCORONA vs. IPMOperational & Financial PerformanceFinancial & Operational Performance for Q1 and H1 FY27Road AheadKey Growth StrategiesAnnexuresManagement Team and Historical Financial Performance ContentsFocused Brand Building ApproachStrong brand recall across Therapeutic Areas
Page 25
25 Future Growth Strategies CORONA Remedies Limited •Improve MR productivity, expanding prescriber base and increasing the number of productsprescribed per prescriber•Intensify engagement with super-specialist prescribers in metro, semi-metro, and urban centersthrough MR networkIncrease market share within the domestic IPM1 •Further grow in women’s health by marketing to infertility specialists, IVF-focused chain hospitals andincreased MR coverage•Expand presence into additional therapeutic areas such as nephrology, central nervous system (CNS),Rheumatology, dermatology & GastroenterologyExpand into other therapeutic areas2 •Launch new products that address unmet patient needs within existing therapeutic areas•Deepen presence in focused therapeutic segments through targeted product expansionsProduct Portfolio Management3 •Expand into areas that complement existing portfolio, enabling entry into newer therapy areas•Maximize the potential of acquisitions and in-licensed products, ensuring sustainable long-termgrowth and value creationStrategic acquisitions and in-licensing agreements4 •Leverage hormone product portfolio, strong R&D capabilities, and differentiated product offerings topenetrate overseas markets•Enter regulated markets and establish credibility with healthcare professionals and regulatoryauthorities worldwideExpand sales in select overseas markets5
Page 26
26 About usOverview of CORONACORONA: Outpacing IPM GrowthCORONA vs. IPMOperational & Financial PerformanceFinancial & Operational Performance for Q1 and H1 FY27Road AheadKey Growth StrategiesAnnexuresManagement Team & Historical Financial Performance ContentsFocused Brand Building ApproachStrong brand recall across Therapeutic Areas
Page 27
27 Over 2 decades of experience in the pharmaceutical industry.Niravkumar Kritikumar MehtaManaging Director & CEO A Chartered Accountant by profession. Has over 2 decades of experience in the finance & pharmaceutical industryBhavin Naresh Bhagat Chief Financial Officer Over 2 decades of experience. Handles global marketing, product planning, and compliance.Sangeeta Thaker President – Global Business Over 2 decades of experience in the pharmaceutical industry.Ankur Kritikumar MehtaJoint Managing Director Over 3 decades of experience. Oversees supply chain operations, production planning, and warehouse management.Bhaven ShahPresident - Commercial Over 2 decades of experience. Handles strategic planning, business development, and acquisitions.Tejas KothariVice President – Corp. Strategy & Business Development Over 2 decades of experience in the pharmaceutical industry.Viral Bhupendrabhai SitwalaWhole-Time Director Over 3 decades of experience. Leads sales and marketing activities and manages product portfolio and regulatory compliance in India.Vijay CharluPresident – India Business 15+ years of experience. Handles secretarial work and statutory compliances.Chetna Prabhatkumar DharajiyaCS & Compliance Officer Professional Senior Management Leading the Way
Page 28
28 Niravkumar Kritikumar MehtaManaging Director & CEO Ankur Kritikumar MehtaJoint Managing Director Viral Bhupendrabhai SitwalaWhole-Time Director Dr. Kiritkumar Laxmidas MehtaChairman and Non-Executive Director Ameetkumar Hiranyakumar DesaiIndependent DirectorHas over 3 decades of experience across sectors like pharmaceuticals, defenceand finance. Monica KanugaIndependent DirectorHas over 3 decades of experience in corporate compliance and governance Shirish Gundopant BelapureIndependent DirectorHas over 3 decades of experience in building quality state of the art manufacturing facilities in pharmaceutical industry Bhaskar Vemban IyerIndependent Director Has over 3 decades of experience across domestic formulation pharmaceutical business Experienced Board of Directors
Page 29
ESG @ CORONA Remedies 29 ESG •Existing solar power plant of 1.3 MW at Bhayla Plant and 4.25 MW in Solar Park Spread across 11.9Acres which saves significant electricity cost•Protection of Environment by Tree Plantation, Distribution of Plant Saplings, initiatives like wearingun-ironed clothes•Effluent Treatment plant (ETP) at Bhayla Plant for achieving zero liquid discharge.•Financial Assistance to Young Talent for promotion of Sports and Education.•Blood donation camps organized at HO and manufacturing facilities.•Investing in Employee training increased by 50%•Promoting Gender Equality. 40% of the total workforce at Solan Plant are female employees.•The World Bank Group awarded the Company with EDGE Advance Certificate recognizing theCompany for energy and water saving measures.•A+ Credit Rating•EU-GMP Certified Plant. One World One Quality.•Serialization and QR Code Technology for product counterfeiting on the strip
Page 30
30 Historical Consolidated Profit & Loss Statement * Excludes one-time statutory impact of New Labor Code Rs.19.1 Cr (Post Tax Rs.14.3 Cr) in FY26 FY23FY24FY25FY26Profit and Loss (₹ Crores)884.1 1,014.5 1,196.4 1,403.2 Revenue from Operations211.0 226.8 236.5 260.9 Cost of Goods Sold673.1 787.6 959.9 1,142.2 Gross Profit76.1%77.6%80.2%81.4%Gross Margin (%)254.8 295.4 346.1 403.0 Employee Cost290.3 337.5 373.8 445.8 Other Expenses128.0 154.7 240.0 293.4 EBITDA14.5%15.3%20.1%20.9%EBITDA Margin (%)20.1 28.3 37.2 37.9 Depreciation & Amortization7.1 6.5 5.9 10.7 Other Income114.9 132.9 208.8 266.2 EBIT4.3 14.4 10.6 7.0 Finance Cost0.2 0.0 0.4 0.3 Share in Profit/(loss) in Associate110.9 118.5 198.5 259.5 Profit before tax (before exceptional items)0.0 0.0 0.0 -19.1 Exceptional Income/(Expense)*110.9 118.5 198.5 240.4 Profit before tax (after exceptional items)26.0 28.0 49.1 55.3 Tax Expense84.9 90.5 149.4 185.1 Reported Profit After Tax0.0 0.0 0.0 14.3 Add: Adjustment for exceptional items (net of tax)*84.9 90.5 149.4 199.4 Adjusted Profit After Tax *9.6%8.9%12.5%14.2%Adjusted Profit After Tax Margin (%)
Page 31
31 Historical Consolidated Balance SheetMar-23Mar-24Mar-25Mar-26Assets (₹ Crores)303.5 540.7 591.0 856.8 Non - Current Assets184.1 191.0 198.7 291.1 Property, plant and equipment64.7 120.6 186.0 143.1 Capital work-in-progress0.5 192.7 171.2 262.8 Intangible assets25.5 25.5 25.9 26.1 Investments accounted as per equity methodFinancial Assets0.1 0.1 0.1 0.2 Investments15.8 3.2 1.3 129.9 Other Financial Assets4.3 0.0 0.0 0.0 Deferred tax assets (net)0.0 0.1 0.0 0.0 Loans8.6 7.5 7.9 3.6 Other non-current assets291.5 289.9 338.9 348.3 Current Assets105.4 98.3 129.5 125.0 Inventories6.0 0.0 0.0 0.0 InvestmentsFinancial Assets87.0 99.9 118.3 145.6 (i) Trade receivables14.5 3.2 3.2 1.8 (ii) Cash and cash equivalents62.2 66.7 66.1 42.3 (iii) Bank balances0.4 0.4 0.4 0.3 Loans0.0 0.0 2.6 0.3 Other Financial Assets16.0 21.4 18.8 33.1 Other Current Assets595.0 830.6 929.9 1,205.1 Total Assets Mar-23Mar-24Mar-25Mar-26Equity & Liabilities (₹ Crores)408.5 480.4 606.3 746.9 Total Equity61.2 61.2 61.2 61.2 Share Capital347.4 419.2 545.2 685.7 Other Equity49.1 126.0 83.9 97.1 Non-Current LiabilitiesFinancial Liabilities0.0 67.0 16.0 0.0 (i) Borrowings24.8 32.0 38.6 66.1 Provisions0.0 4.3 8.3 12.2 Deferred tax liabilities (net)0.5 0.0 0.0 0.0 Other Financial Liabilities23.8 22.6 21.0 18.9 Lease Liabilities137.4 224.2 239.6 361.2 Current LiabilitiesFinancial Liabilities2.3 67.1 46.7 142.9 (i) Borrowings94.4 114.3 143.5 147.1 (ii) Trade Payables8.0 5.4 4.8 19.7 (iii) Other Financial Liabilities8.6 6.8 8.4 7.0 Other Current Liabilities18.4 2.2 2.5 3.1 Lease Liabilities3.8 4.8 6.3 8.4 Current Tax Liabilities1.8 23.5 27.4 33.0 Provisions595.0 830.6 929.9 1,205.1 Total Equity & Liabilities
Page 32
32 Historical Consolidated Abridged Cash Flow StatementFY23FY24FY25FY26Abridged Cash Flow Statement (₹ Crores)110.9 118.5 198.5 240.4 Net Profit Before Tax22.6 46.9 52.3 44.4 Adjustments for: Non - Cash Items / Other Investment or Financial Items133.4 165.3 250.8 284.8 Operating profit before working capital changes-4.9 9.3 -17.1 -5.9 Changes in working capital128.5 174.7 233.8 278.9 Cash generated from Operations25.8 17.9 -43.3 -49.4 Direct taxes paid (net of refund)102.7 156.8 190.5 229.5 Net Cash from Operating Activities-50.2 -266.6 -83.9 -256.1 Net Cash from Investing Activities-44.7 98.5 -106.6 25.3 Net Cash from Financing Activities7.7 -11.3 0.1 -1.4 Net Increase/(Decrease) in Cash and Cash equivalents6.8 14.5 3.2 3.2 Add: Cash & Cash equivalents at the beginning of the year14.5 3.2 3.2 1.8 Cash & Cash equivalents at the end of the year
Page 33
33 Historical Financial Statement *Excludes onetime statutory impact of New Labor Code Rs.19.1 Cr (Post Tax Rs.14.3 Cr) for FY26884.11,014.51,196.41,403.2FY23 FY24 FY25FY2617%EBITDA (₹ Crores)PAT (₹ Crores)Revenue (₹ Crores)128.0154.7240.0293.4FY23 FY24 FY25FY26+32%84.990.5149.4199.4FY23 FY24 FY25FY26*+33%
Page 34
34 ROCE (%)OCF/EBITDA (%)ROE (%)Net working Capital DaysHistorical Financial Ratios *ROE and ROCE for FY26 is annualised & Excludes onetime statutory impact of New Labor Code Rs.19.1 Cr (Post Tax Rs.14.3 Cr)FY23 FY24 FY25FY26*28.4%31.2%41.3%40.8%FY23 FY24 FY25FY26*23.3%20.4%27.5%29.2% FY23 FY24 FY25FY2680.2%101.3%79.4%78.2%31232427FY23 FY24 FY25FY26
Page 35
THANK YOUFor further information, please contact:CORONA Remedies LimitedCIN: L24231GJ2004PLC044656Ms. Chetna Dharajiya – Company Secretary & Compliance Officerchetnad@coronaremedies.comMr. Sagar Shroff / Mr. Tanay Shahsagar.shroff@sgapl.net / tanay.shah@sgapl.net+91 98205 19303 / +91 98333 91899 Strategic Growth Advisors Private Limited (SGA)CIN: U74140MH2010PTC204285